---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-047196"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:01:40.414416+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q4/FY2024 results: cash $164M, R&D spend up, protocol deviation in SSc trial

## Summary
- Cash and equivalents $164M as of Dec 31, 2024, providing runway into first half of 2026.
- R&D expenses for FY2024 were $97.2M, up from $55.4M in FY2023.
- Enrolled 33 patients across RESET program as of Mar 14, 2025; FDA meeting on myositis trial designs on track for 1H25.
- Protocol deviation in RESET-SSc: patient infused with fever developed grade 3 ICANS; IDMC recommended trial continue.
- Expanded CDMO agreement with Lonza for rese-cel clinical product supply starting 2H25.

## SEC filing metadata
- accession: 0000950170-25-047196
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000095017025047196/0000950170-25-047196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000095017025047196/caba-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-047196
- JSON: https://secwatch.observer/filing/0000950170-25-047196.json
- Plain text: https://secwatch.observer/filing/0000950170-25-047196.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.